A higher amount barely changed the weight result in a 76 week trial

A late stage trial of an injected weight loss drug tested two amounts of it against an inactive injection. Over 76 weeks the higher amount produced only a slightly larger average weight reduction than the lower one, while side effects in the stomach and gut were more common with it. The results appeared in the New England Journal of Medicine in August 2026 [1].

What the trial did

Seven hundred and twenty five adults took part. All had a body mass index of 30 or higher, or of 27 or higher with at least one weight related health problem, and none had diabetes. Chance decided which of three groups each person joined: a lower weekly injection of survodutide, a higher weekly injection of it, or placebo, an inactive substitute given so that investigators can separate what a medicine did from what would have happened anyway. Two hundred and forty one people went into the lower group, 242 into the higher group and 242 into the placebo group, and everyone also received counselling on food and activity. Average age was 47.1 years, average body mass index 37.9, and average weight 108.8 kilograms [1][2].

Survodutide acts on two receptors rather than one. Receptors are docking points on a cell surface, each shaped to fit a particular hormone. This molecule switches on the GLP-1 receptor, the one the familiar weight loss medicines act on, and the glucagon receptor, which researchers study for its role in energy use and in liver fat [1].

The numbers the journal printed

The main measurement was percent change in body weight from the start to week 76. Under the count the investigators named in advance as primary, the lower amount produced an average reduction of 12.2 percent, with a range of statistical uncertainty running from 13.6 to 10.8 percent. The higher amount produced 13.0 percent, with a range from 14.4 to 11.6. The placebo group came in at 5.4 percent, with a range from 6.9 to 4.0. A reduction of at least 5 percent was reached by 72.6 percent, 71.9 percent and 46.3 percent of the three groups in that order [1].

Two things in that list are worth sitting with. The first is that the higher amount barely separated from the lower one, and that slightly fewer of the people taking it reached the 5 percent mark. The second is the comparison group, which lost an average of 5.4 percent on an inactive injection and counselling. That is a lot, and it narrows the space the medicine had to work in [1].

Side effects moved the other way. Symptoms in the stomach and gut, meaning nausea, vomiting, diarrhoea and related trouble, were reported by 80.9 percent of the lower group, 89.7 percent of the higher group and 47.9 percent of the placebo group. The report describes them as typically mild to moderate. No deaths were reported [1].

The figure released in April, and the figure printed in August

Months before any of this reached a journal, the company that discovered the molecule published an announcement of the headline result [4].

Adults living with obesity or overweight, without type 2 diabetes, who were treated with survodutide experienced sustained weight loss of up to an average of 16.6% after 76 weeks using the efficacy estimand, a statistically significant decrease versus 3.2% in the placebo arm (p<0.0001).

Zealand Pharma, results announcement, April 2026 [4]

Nothing in that sentence is untrue, and it names its own count. An estimand is the exact question a trial's main number answers. The efficacy estimand asks what happens in people while they are actually taking the medicine. The treatment regimen estimand, the one this trial named as primary and the one the journal printed, keeps everyone in the group they were assigned to, including those who stopped early. Under the first count the two figures are 16.6 percent and 3.2 percent. Under the second they are 13.0 percent and 5.4 percent [1][4].

Both describe the same 725 people. The first answers what the medicine does when taken; the second answers what becomes of a group started on it. Neither is wrong, and a reader who meets only one has half the record [1][4].

A second trial, about the liver

A separate late stage trial of the same molecule, published in Nature Medicine in 2026, enrolled 216 adults who had obesity together with fatty liver disease linked to metabolic problems. One hundred and forty six received the medicine and 70 received placebo, for 48 weeks, and liver fat was measured by scan. A reduction of at least 30 percent in liver fat was reached by 84.2 percent of the treated group against 24.3 percent on placebo under the on treatment count, and by 68.5 percent against 28.6 percent under the count that keeps everyone as assigned [3].

The authors set out their own limits: 48 weeks is short, and participants came from only two countries, the United States and Spain. Liver fat on a scan is a measurement rather than an outcome, and whether less of it means fewer people develop liver failure later is a question this trial did not ask [3].

What it does not show

Nothing here compares the medicine against another medicine. The only comparison run was against an inactive injection, so any ranking against the injections already in use would have to come from a trial nobody has done. The registry entry shows the study started in November 2023 and finished collecting its main measurement in December 2025, and it stops at 76 weeks, which leaves year three unmeasured [1][2].

The population is narrow in the usual way: adults with obesity, no diabetes, near 108 kilograms on average at the start. And the side effect figures are the part of this record least likely to soften with familiarity. Close to nine in ten people on the higher amount reported symptoms in the stomach and gut, for a main result that barely moved away from the lower amount [1].